The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $135.36

Today's change-3.46 -2.49%
Updated February 11 4:00 PM EST. Delayed by at least 15 minutes.
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $135.36

Today's change-3.46 -2.49%
Updated February 11 4:00 PM EST. Delayed by at least 15 minutes.

Alexion Pharmaceuticals Inc down (U.S.)$3.46

Alexion Pharmaceuticals Inc closed sharply lower Thursday, dropping (U.S.)$3.46 or 2.49% to (U.S.)$135.36. Over the last five days, shares have lost 7.30% and sit 3.72% above their 52-week low. This security has underperformed the S&P 500 by 10.41% during the last year.

Key company metrics

  • Open(U.S.) $134.52
  • Previous close(U.S.) $138.82
  • High(U.S.) $137.63
  • Low(U.S.) $134.25
  • Bid / Ask(U.S.) $132.01 / (U.S.) $137.00
  • YTD % change-29.04%
  • Volume1,402,017
  • Average volume (10-day)2,834,647
  • Average volume (1-month)2,071,668
  • Average volume (3-month)1,651,414
  • 52-week range(U.S.) $130.51 to (U.S.) $208.88
  • Beta0.95
  • Trailing P/E177.25×
  • P/E 1 year forward26.63×
  • Forward PEG1.33×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.76
Updated February 11 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+5.54%

Based on its net profit margin of 5.54%, Alexion Pharmaceuticals Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.81%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue701667636600
Total other revenue--------
Total revenue701667636600
Gross profit643613584531
Total cost of revenue58545269
Total operating expense604512455497
Selling / general / administrative242213221187
Research & development191161126216
Depreciation / amortization804165
Interest expense (income), net operating--------
Unusual expense (income)33435019
Other operating expenses, total--------
Operating income97155181104
Interest income (expense), net non-operating-23-----1
Gain (loss) on sale of assets--------
Other--------
Income before tax75139177107
Income after tax67-18417091
Income tax, total8323716
Net income67-18417091
Total adjustments to net income--------
Net income before extra. items67-18417091
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items67-18417091
Inc. avail. to common incl. extra. items67-18417091
Diluted net income67-18417091
Dilution adjustment--------
Diluted weighted average shares228226205202
Diluted EPS excluding extraordinary itemsvalue per share0.29-0.810.830.45
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share0.42-0.691.070.53